NYSE: BMYBristol Myers Squibb Co Stock
$74.53+0.08 (+0.11%)
Updated Feb 6, 2023
BMY Price
$74.53
Fair Value Price
N/A
Market Cap
$158.46B
52 Week Low
$65.60
52 Week High
$81.44
P/E
24.12x
P/B
4.85x
P/S
3.25x
PEG
0.61x
Dividend Yield
2.94%
Revenue
$46.74B
Earnings
$6.68B
Gross Margin
78.8%
Operating Margin
16.47%
Profit Margin
14.3%
Debt to Equity
2
Operating Cash Flow
$14B
Beta
0.55
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BMY Overview
Bristol-Myers Squibb Company is one of the world's largest pharmaceutical companies. It manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders. Unlike some of its more diversified peers, Bristol-Myers has exited several nonpharmaceutical businesses to focus on branded specialty drugs. The company was founded in 1887 and is headquartered in New York, NY.
Zen Score
–
Industry Average (43)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BMY scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BMY ($74.53) is trading above its intrinsic value of $65.55, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BMY is poor value based on its earnings relative to its share price (24.12x), compared to the US market average (14.99x)
P/E vs Market Valuation
BMY is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more BMY due diligence checks available for Premium users.
Be the first to know about important BMY news, forecast changes, insider trades & much more!
BMY News
Valuation
BMY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
24.12x
Industry
30.8x
Market
14.99x
BMY is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BMY is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
BMY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.85x
Industry
5.14x
BMY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BMY price to earnings growth (PEG)
For valuing profitable companies with growth potential
BMY is good value based... subscribe to Premium to read more.
PEG Value Valuation
BMY's financial health
Profit margin
Revenue
$11.2B
Net Income
$1.6B
Profit Margin
14.3%
BMY's Earnings (EBIT) of $7.70B... subscribe to Premium to read more.
Interest Coverage Financials
BMY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$98.2B
Liabilities
$65.5B
Debt to equity
2
BMY's short-term assets ($26.80B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BMY's long-term liabilities ($46.53B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BMY's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BMY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$3.7B
Investing
-$2.1B
Financing
-$4.5B
BMY's operating cash flow ($13.82B)... subscribe to Premium to read more.
Debt Coverage Financials
BMY vs General Drug Manufacturer Stocks
Bristol Myers Squibb Co Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.